Cellectis (NASDAQ: CLLS) sets August 6 date for Q2 2026 results
Rhea-AI Filing Summary
Cellectis S.A., a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, stated it will report second quarter 2026 financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
The company indicated it will not host a conference call for these results and directed investors to its website and investor relations contacts for the press release and any questions. Cellectis uses an allogeneic approach to CAR T immunotherapies and is listed on Nasdaq and Euronext Growth.
Positive
- None.
Negative
- None.
Key Figures
Date of report: July 30, 2026
Q2 2026 quarter end: June 30, 2026
Results release date: August 6, 2026
3 metrics
Date of report
July 30, 2026
Date of the company’s Form 6-K report
Q2 2026 quarter end
June 30, 2026
Quarter end date for which Cellectis will report results
Results release date
August 6, 2026
Date Cellectis will release Q2 2026 financial results after US market close
Key Terms
Form 6-K, foreign private issuer, allogeneic approach, CAR T immunotherapies
4 terms
Form 6-K regulatory
"Form 6-K report of foreign private issuer"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"Report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
allogeneic approach medical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
CAR T immunotherapies medical
"An allogeneic approach for CAR T immunotherapies in oncology"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
When will Cellectis (CLLS) release its Q2 2026 financial results?
Cellectis will release its Q2 2026 financial results on Thursday, August 6, 2026 after the close of the US market. The results cover the company’s second quarter and will be detailed in a press release available to investors.
Will Cellectis (CLLS) hold a conference call for its Q2 2026 results?
Cellectis stated it will not host a conference call to discuss its Q2 2026 results. Instead, investors are directed to the company’s website and investor relations contacts for the press release and any follow-up questions.
What reporting period will Cellectis (CLLS) Q2 2026 results cover?
The Q2 2026 results from Cellectis will cover the quarter ending June 30, 2026. This corresponds to the company’s financial performance for the second quarter of 2026, which will be summarized in the upcoming earnings press release.
Where can investors access the Cellectis (CLLS) Q2 2026 earnings press release?
The Q2 2026 earnings press release will be available in the Investors section of Cellectis’ website, under press releases. Investors can visit https://www.cellectis.com/en/investors/press-releases/ to review the detailed financial information once published.
What kind of company is Cellectis (CLLS) and where is it listed?
Cellectis is a clinical-stage biotechnology company using gene-editing to develop cell and gene therapies, including allogeneic CAR T treatments. It is listed on the Nasdaq Global Market under CLLS and on Euronext Growth under ALCLS.